Canadian Cancer Trials Group Bulletins


Canadian Cancer Trials Group IND.221 Presented at TAT

Canadian Cancer Trials Group IND.221 -- A Dose-Ranging Study of IPH2201 in Patients with High Grade Serous Carcinoma of Ovarian, Fallopian Tube or Peritoneal Origin

Dr. Lesley Seymour, Investigational New Drug (IND) Program Director, recently presented Canadian Cancer Trials Group IND.221 at the Targeted Anticancer Therapies Conference in Paris. This phase I trial is investigating IPH2201, a first-in-class NKG2A checkpoint inhibitor, in women with high grade serous carcinoma (HGSC) of ovarian, fallopian tube or peritoneal origin. The primary objective of the trial is to confirm the recommended phase II dose (RP2D) in cancer patients. Secondary objectives include safety, toxicity and pharmacokinetics, pharmacodynamic effects, anti-drug antibodies, and to explore the efficacy of IPH2201 as a single agent in platinum-resistant or sensitive HGSC.

Canadian Cancer Trials Group, in collaboration with Innate Pharma, will conduct the trial in Canada and plans to enroll 38 patients with ovarian cancer. In the first part of the study, patients will receive IPH2201 at one of three dose levels. Thereafter, 20 additional patients will be enrolled, in two groups, including patients whose ovarian cancer is felt to be either platinum sensitive or resistant.

Dr. Seymour's presentation can be found on the 13th International Congress on Targeted Anticancer Therapeutics website using this link ...

Additionally, Innate Pharma has posted a release about the trial on its website which you can find using this link ...

The trial should be activated very soon.